Um inibidor da via hedgehog tópico. Ensaios de fase 2 e 3 que avaliaram a efetividade do patidegibe em pacientes com síndrome de Gorlin ou carcinoma basocelular não-Gorlin estão em andamento.[92]ClinicalTrials.gov. Study of patidegib topical gel, 2%, for the reduction of disease burden of persistently developing basal cell carcinomas (BCCs) in subjects with basal cell nevus syndrome (Gorlin syndrome). NCT03703310. Mar 2021 [internet publication].
https://clinicaltrials.gov/ct2/show/NCT03703310
[93]ClinicalTrials.gov. Trial of patidegib gel 2%, 4%, and vehicle to decrease the number of surgically eligible basal cell carcinomas in Gorlin syndrome patients. NCT02762084. Jul 2020 [internet publication].
https://clinicaltrials.gov/ct2/show/NCT02762084
[94]ClinicalTrials.gov. Clinical trial of patidegib gel 2%, 4%, and vehicle applied once or twice daily to decrease the GLI1 biomarker in sporadic nodular basal cell carcinomas (BCC). NCT02828111. Jan 2019 [internet publication].
https://clinicaltrials.gov/ct2/show/NCT02828111
O uso deste conteúdo está sujeito ao nosso aviso legal